GET DAILY SIGNALSEyePoint Pharmaceuticals (EYPT) Falls -89% After Phase 3 Trial Miss
Key Takeaways
- EyePoint Pharmaceuticals (EYPT) fell roughly 89% over the last 30 days, from about $3.01 to about $0.32, after the second DURAVYU wet AMD Phase 3 trial missed its primary endpoint.
- The collapse follows the August 2026 LUGANO trial failure, prompting the company to terminate its entire wet AMD program and cut approximately 53% of its workforce.
- EyePoint is redirecting resources to diabetic macular edema (DME), where Phase 3 COMO and CAPRI trials are fully enrolled with topline data expected in the fourth quarter of 2027.
- Third-quarter 2026 results reported a net loss of $95.6 million ($1.07 per share) and roughly $118 million in cash and investments as of September 30.
- The shares now trade well below $1, creating Nasdaq minimum-bid compliance risk and uncertainty around future financing.
EyePoint Pharmaceuticals (EYPT) Company Overview and Market Position
EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing treatments for serious retinal diseases. Its lead candidate, DURAVYU (vorolanib intravitreal insert), combines a selective, patent-protected tyrosine kinase inhibitor with the company's bioerodible Durasert E sustained-delivery technology, designed to release drug for at least six months from a single injection. Vorolanib's multi-mechanism action targets both VEGF-mediated vascular permeability and IL-6/JAK1-mediated inflammation. Investors have closely followed EYPT because of its large addressable market in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), where DURAVYU aimed to match the efficacy of standard-of-care anti-VEGF therapies such as Regeneron's (REGN) Eylea while sharply reducing injection frequency. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
EyePoint Pharmaceuticals (EYPT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, EYPT declined approximately 89%, falling from a closing price of $3.01 on October 14 to about $0.32 by mid-November. The single largest move occurred on October 19, when the stock dropped 85.3% to close at $0.44 after the LUCIA trial readout, on volume that surged to more than 100 million shares versus a typical daily range of roughly 1–3 million shares.
The quarterly picture is even steeper. Three months ago the stock traded in the mid-teens, but the combination of the LUGANO failure in August 2026 and the LUCIA failure in October 2026 drove EYPT down roughly 98% over the period, from about $14.75 to under $0.50. The shares remain far below their 52-week high of $19.11.
What Drove EYPT Stock Price in the Last 30 Days
The dominant catalyst was the October 19 disclosure that the Phase 3 LUCIA trial of DURAVYU in wet AMD failed to meet its primary endpoint of non-inferiority in best-corrected visual acuity versus aflibercept. DURAVYU improved vision by 2.5 letters over 52 weeks compared with a 6-letter improvement for Eylea, a gap that fell outside the non-inferiority margin, even though the trial met key secondary endpoints including a 38% reduction in treatment burden.
In response, EyePoint's board approved ending the pivotal wet AMD trials early and reducing the workforce by approximately 53%, targeting roughly $30 million in annualized savings with about $9 million in one-time severance-related charges. The company also reported third-quarter 2026 results, including a $95.6 million net loss and $118 million in cash as of September 30. Analysts adjusted their outlooks, with Stifel lowering its price target to $5 from $6 while maintaining a Buy rating, and several securities law firms announced investigations. The slide below $1 also raised Nasdaq minimum-bid compliance concerns.
What Drove EYPT Stock Performance Over the Last Quarter
The quarterly decline reflects two consecutive late-stage clinical setbacks. In August, the first pivotal trial, LUGANO, missed its primary endpoint, sending shares down about 67% to $4.87. The second failure in LUCIA eliminated the remaining near-term catalyst in wet AMD and forced a strategic reset. Previously, sell-side targets had ranged from the $20s into the $60s, but the repeated misses led to sharp downward revisions and a shift in focus to the DME program, whose pivotal readouts are not expected until the fourth quarter of 2027. The result has been a re-rating of EYPT from a company with imminent catalysts to one trading below the value of its cash, reflecting a binary bet on a single future readout.
EYPT Stock Forecast Drivers: What Investors Should Watch Next
Investors will focus on the Phase 3 COMO and CAPRI trials in diabetic macular edema, with topline data anticipated in the fourth quarter of 2027. The company has indicated its cash is expected to fund operations into late third-quarter 2027, so whether it can reach the DME readout without additional financing, and the potential dilution from any capital raise at current prices, are central considerations. Other factors include execution of the restructuring, additional analyses of the pooled LUGANO and LUCIA data for any future wet AMD path, and Nasdaq listing compliance. These forward-looking items are inherently uncertain, and clinical outcomes remain binary. From what I see, I’m watching this closely as the company pivots.
Exploring Automated Strategies
In my analysis of high-volatility situations like this, I often turn to Tickeron’s Trending AI Robots to review curated automated trading strategies. This page surfaces top-performing bots across thousands of tickers, helping compare approaches and align them with personal risk tolerance and market views for an additional data-driven perspective.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
EYPT in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 12, 2026
EYPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 39 cases where EYPT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for EYPT just turned positive on November 02, 2026. Looking at past instances where EYPT's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.
Following a +12.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where EYPT advanced for three days, in 238 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EYPT as a result. In 59 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EYPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for EYPT entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.187) is normal, around the industry mean (3.498). P/E Ratio (-0.096) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.380) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (101.010) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. EYPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EYPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of ophthalmic pharmaceuticals
Industry Biotechnology
Advertisement